JENNIFER WALSH: Open Payments
NPI 1447702360 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,901 in 134 payments from 21 companies in 2025. Trend: 2023 $6,788 · 2024 $4,686 · 2025 $2,901
Food & beverage: $2,901
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 46 | $1,048 |
| Lundbeck LLC | 16 | $258 |
| Neurocrine BioSciences, Inc. | 6 | $225 |
| Amgen Inc. | 5 | $217 |
| PFIZER INC. | 11 | $197 |
| Novartis Pharmaceuticals Corporation | 15 | $190 |
| ARGENX US, INC. | 9 | $154 |
| Eisai Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $120 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
Products named: QULIPTA, BOTOX, UBRELVY, VYEPTI, INGREZZA, UPLIZNA, NURTEC ODT, KESIMPTA.
Industry payments across NV — which companies pay providers there.
